Stand Up To Cancer works relentlessly to offer the newest, most effective, and most promising cancer treatments to patients quickly by bringing together the best minds to collaborate, innovate, and share cancer research.
Stand Up To Cancer enables scientific breakthroughs by funding collaborative, multidisciplinary, multi-institutional scientific cancer research teams and investigators. Thanks to the support of our dedicated partners and the entertainment community, SU2C is able to bring widespread attention to cancer research and treatments.
We’re all in this together! Learn how to get involved and make a monumental impact. Join our community of passionate supporters who are committed to helping patients gain rapid access to better treatments.
Research is changing the way cancer is being treated. If you’ve been diagnosed with cancer, a clinical trial may offer access to the latest and most promising science, while helping to light the path for future survivors.
Stand Up To Cancer was created to accelerate groundbreaking cancer research that will get promising new cancer treatments to patients quickly. We won’t stop until every cancer patient is a long-term cancer survivor.
Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018 Jul 14;392(10142):123-133.